Naturally-occurring human serum antibodies to inner core lipopolysaccharide epitopes of Neisseria meningitidis protect against invasive meningococcal disease caused by isolates displaying homologous inner core structures

Vaccine

Volumn 26, Issue 51, 2008, Pages 6655-6663

  Jäkel, Anne ^a   Plested, Joyce S ^a   Hoe, J Claire ^b   Makepeace, Katherine ^b   Gidney, Margaret Anne J ^c   Lacelle, Suzanne ^c   St Michael, Frank ^c   Cox, Andrew D ^c   Richards, James C ^c   Moxon, E Richard ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c NATIONAL RESEARCH COUNCIL CANADA   (Canada)

Author keywords

Affinity purified antibodies; Lipopolysaccharide; Neisseria meningitides

Indexed keywords

BACTERIUM ANTIBODY; BACTERIUM LIPOPOLYSACCHARIDE; IMMUNOGLOBULIN G; MENINGOCOCCUS ANTIBODY; MENINGOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIGEN RECOGNITION; ARTICLE; CHILD; CONTROLLED STUDY; EPITOPE MAPPING; HUMAN; INFANT; INFECTION RESISTANCE; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; NONHUMAN; NORMAL HUMAN; PASSIVE IMMUNIZATION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN PURIFICATION; RAT; SERUM BACTERICIDAL ACTIVITY;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ANIMALS; ANTIBODIES, BACTERIAL; CHILD, PRESCHOOL; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULIN G; INFANT; LIPOPOLYSACCHARIDES; MENINGOCOCCAL INFECTIONS; MIDDLE AGED; NEISSERIA MENINGITIDIS; RATS; SERUM BACTERICIDAL TEST; YOUNG ADULT;

EID: 58149199760     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.09.041     Document Type: Article

References (58)

1. Cartwright K. Meningococcal carriage and disease. In: Cartwright K. (Ed). Meningococcal disease (1995), John Wiley and Sons Ltd. 115-146
2. Rappuoli R., Pollard A.J., and Moxon E.R. Meningococcal conjugate and protein-based vaccines. In: Levine M.M., Kaper J.B., Rappuoli R., Liu M.A., and Good M.F. (Eds). New generation vaccines. Third edition (2004), Marcel Dekker Inc. 421-426
3. Finne J., Leinonen M., and Makela P.H. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet 2 8346 (1983) 355-357
4. Bjune G., Gronnesby J.K., Hoiby E.A., Closs O., and Nokleby H. Results of an efficacy trial with an outer membrane vesicle vaccine against systemic serogroup B meningococcal disease in Norway. NIPH Ann 14 2 (1991) 125-130 [discussion 30-32]
5. Boslego J., Garcia J., Cruz C., Zollinger W., Brandt B., Ruiz S., et al. Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease. Vaccine 13 9 (1995) 821-829
6. de Moraes J.C., Perkins B.A., Camargo M.C., Hidalgo N.T., Barbosa H.A., Sacchi C.T., et al. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet 340 8827 (1992) 1074-1078
7. Perkins B.A., Jonsdottir K., Briem H., Griffiths E., Plikaytis B.D., Hoiby E.A., et al. Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland. J Infect Dis 177 3 (1998) 683-691
8. Sierra G.V., Campa H.C., Varcacel N.M., Garcia I.L., Izquierdo P.L., Sotolongo P.F., et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann 14 2 (1991) 195-207 [discussion 08-10]
9. Christodoulides M., Brooks J.L., Rattue E., and Heckels J.E. Immunization with recombinant class 1 outer-membrane protein from Neisseria meningitidis: influence of liposomes and adjuvants on antibody avidity, recognition of native protein and the induction of a bactericidal immune response against meningococci. Microbiology 144 Part 11 (1998) 3027-3037
10. Jolley K.A., Appleby L., Wright J.C., Christodoulides M., and Heckels J.E. Immunization with recombinant Opc outer membrane protein from Neisseria meningitidis: influence of sequence variation and levels of expression on the bactericidal immune response against meningococci. Infect Immun 69 6 (2001) 3809-3816
11. Wright J.C., Williams J.N., Christodoulides M., and Heckels J.E. Immunization with the recombinant PorB outer membrane protein induces a bactericidal immune response against Neisseria meningitidis. Infect Immun 70 8 (2002) 4028-4034
12. Wright J.C., Plested J., and Moxon E.R. Genetics, structure and function of lipopolysaccharide. In: Frosch M., and Maiden M.C. (Eds). Handbook of meningococcal disease (2006), Wiley-VCH 163-179
13. Kahler C.M., and Stephens D.S. Genetic basis for biosynthesis, structure, and function of meningococcal lipooligosaccharide (endotoxin). Crit Rev Microbiol 24 4 (1998) 281-334
14. Di Fabio J.L., Michon F., Brisson J., and Jennings H.J. Structure of L1 and L6 core oligosaccharide epitopes of Neisseria meningitidis. Can J Chem 68 (1990) 1029-1034
15. Gamian A., Beurret M., Michon F., Brisson J.R., and Jennings H.J. Structure of the L2 lipopolysaccharide core oligosaccharides of Neisseria meningitidis. J Biol Chem 267 2 (1992) 922-925
16. Jennings H.J., Johnson K.G., and Kenne L. The structure of an R-type oligosaccharide core obtained from some lipopolysaccharides of Neisseria meningitidis. Carbohydr Res 121 (1983) 233-241
17. Kogan G., Uhrin D., Brisson J.R., and Jennings H.J. Structural basis of the Neisseria meningitidis immunotypes including the L4 and L7 immunotypes. Carbohydr Res 298 3 (1997) 191-199
18. Michon F., Beurret M., Gamian A., Brisson J.R., and Jennings H.J. Structure of the L5 lipopolysaccharide core oligosaccharides of Neisseria meningitidis. J Biol Chem 265 13 (1990) 7243-7247
19. Pavliak V., Brisson J.R., Michon F., Uhrin D., and Jennings H.J. Structure of the sialylated L3 lipopolysaccharide of Neisseria meningitidis. J Biol Chem 268 19 (1993) 14146-14152
20. Scholten R.J., Kuipers B., Valkenburg H.A., Dankert J., Zollinger W.D., and Poolman J.T. Lipo-oligosaccharide immunotyping of Neisseria meningitidis by a whole-cell ELISA with monoclonal antibodies. J Med Microbiol 41 4 (1994) 236-243
21. Wakarchuk W.W., Gilbert M., Martin A., Wu Y., Brisson J.R., Thibault P., et al. Structure of an alpha-2,6-sialylated lipooligosaccharide from Neisseria meningitidis immunotype L1. Eur J Biochem 254 3 (1998) 626-633
22. Cox A.D., Li J., Brisson J.R., Moxon E.R., and Richards J.C. Structural analysis of the lipopolysaccharide from Neisseria meningitidis strain BZ157 galE: localisation of two phosphoethanolamine residues in the inner core oligosaccharide. Carbohydr Res 337 16 (2002) 1435-1444
23. Mackinnon F.G., Cox A.D., Plested J.S., Tang C.M., Makepeace K., Coull P.A., et al. Identification of a gene (lpt-3) required for the addition of phosphoethanolamine to the lipopolysaccharide inner core of Neisseria meningitidis and its role in mediating susceptibility to bactericidal killing and opsonophagocytosis. Mol Microbiol 43 4 (2002) 931-943
24. Wright J.C., Hood D.W., Randle G.A., Makepeace K., Cox A.D., Li J., et al. lpt6, a gene required for addition of phosphoethanolamine to inner-core lipopolysaccharide of Neisseria meningitidis and Haemophilus influenzae. J Bacteriol 186 20 (2004) 6970-6982
25. Jennings M.P., Srikhanta Y.N., Moxon E.R., Kramer M., Poolman J.T., Kuipers B., et al. The genetic basis of the phase variation repertoire of lipopolysaccharide immunotypes in Neisseria meningitidis. Microbiology 145 Part 11 (1999) 3013-3021
26. Cox A.D., Zou W., Gidney M.A., Lacelle S., Plested J.S., Makepeace K., et al. Candidacy of LPS-based glycoconjugates to prevent invasive meningococcal disease: developmental chemistry and investigation of immunological responses following immunization of mice and rabbits. Vaccine 23 43 (2005) 5045-5054
27. Plested J.S., Makepeace K., Jennings M.P., Gidney M.A., Lacelle S., Brisson J., et al. Conservation and accessibility of an inner core lipopolysaccharide epitope of Neisseria meningitidis. Infect Immun 67 10 (1999) 5417-5426
28. Goldschneider I., Gotschlich E.C., and Artenstein M.S. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med 129 6 (1969) 1307-1326
29. Trotter C., Findlow J., Balmer P., Holland A., Barchha R., Hamer N., et al. Seroprevalence of bactericidal and anti-outer membrane vesicle antibodies to Neisseria meningitidis group B in England. Clin Vaccine Immunol 14 7 (2007) 863-868
30. Guttormsen H.K., Wetzler L.M., and Solberg C.O. Humoral immune response to class 1 outer membrane protein during the course of meningococcal disease. Infect Immun 62 4 (1994) 1437-1443
31. Mandrell R.E., and Zollinger W.D. Human immune response to meningococcal outer membrane protein epitopes after natural infection or vaccination. Infect Immun 57 5 (1989) 1590-1598
32. Griffiss J.M., Brandt B.L., Broud D.D., Goroff D.K., and Baker C.J. Immune response of infants and children to disseminated infections with Neisseria meningitidis. J Infect Dis 150 1 (1984) 71-79
33. Jennings M.P., van der Ley P., Wilks K.E., Maskell D.J., Poolman J.T., and Moxon E.R. Cloning and molecular analysis of the galE gene of Neisseria meningitidis and its role in lipopolysaccharide biosynthesis. Mol Microbiol 10 2 (1993) 361-369
34. van der Ley P., Kramer M., Martin A., Richards J.C., and Poolman J.T. Analysis of the icsBA locus required for biosynthesis of the inner core region from Neisseria meningitidis lipopolysaccharide. FEMS Microbiol Lett 146 2 (1997) 247-253
35. Jennings M.P., Hood D.W., Peak I.R., Virji M., and Moxon E.R. Molecular analysis of a locus for the biosynthesis and phase-variable expression of the lacto-N-neotetraose terminal lipopolysaccharide structure in Neisseria meningitidis. Mol Microbiol 18 4 (1995) 729-740
36. Westphal O., and Jann J.K. Bacterial lipopolysaccharide extraction with water-phenol and further applications of the procedure. Methods Carbohydr Chem 43 (1965) 83-91
37. Karkhanis Y.D., Zeltner J.Y., Jackson J.J., and Carlo D.J. A new and improved microassay to determine 2-keto-3-deoxyoctonate in lipopolysaccharide of Gram-negative bacteria. Anal Biochem 85 2 (1978) 595-601
38. Collins C.L., Salt P., McCarthy N., Chantler T., Lane L., Hemme F., et al. Immunogenicity and safety of a low-dose diphtheria, tetanus and acellular pertussis combination vaccine with either inactivated or oral polio vaccine as a pre-school booster in UK children. Vaccine 22 31-32 (2004) 4262-4269
39. MacLennan J.M., Shackley F., Heath P.T., Deeks J.J., Flamank C., Herbert M., et al. Safety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants: a randomized controlled trial. J Am Med Assoc 283 21 (2000) 2795-2801
40. Gidney M.A., Plested J.S., Lacelle S., Coull P.A., Wright J.C., Makepeace K., et al. Development, characterization, and functional activity of a panel of specific monoclonal antibodies to inner core lipopolysaccharide epitopes in Neisseria meningitidis. Infect Immun 72 1 (2004) 559-569
41. Hou S.J., Saksena R., and Kovac P. Preparation of glycoconjugates by dialkyl squarate chemistry revisited. Carbohydr Res 343 2 (2008) 196-210
42. DuBois M., Gilles K.A., Hamilton J.K., Rebers P.A., and Smith F. Colorimetric method for determination of sugars and related substances. Anal Chem 28 3 (1956) 350-356
43. Plested J.S., Gidney M.A., Coull P.A., Griffiths H.G., Herbert M.A., Bird A.G., et al. Enzyme linked immunosorbent assay (ELISA) for the detection of serum antibodies to the inner core lipopolysaccharide of Neisseria meningitidis group B. J Immunol Methods 237 1-2 (2000) 73-84
44. Plested J.S., Harris S.L., Wright J.C., Coull P.A., Makepeace K., Gidney M.A., et al. Highly conserved Neisseria meningitidis inner-core lipopolysaccharide epitope confers protection against experimental meningococcal bacteremia. J Infect Dis 187 8 (2003) 1223-1234
45. Plested J.S., Ferry B.L., Coull P.A., Makepeace K., Lehmann A.K., MacKinnon F.G., et al. Functional opsonic activity of human serum antibodies to inner core lipopolysaccharide (galE) of serogroup B meningococci measured by flow cytometry. Infect Immun 69 5 (2001) 3203-3213
46. Joiner K.A., Warren K.A., Brown E.J., Swanson J., and Frank M.M. Studies on the mechanism of bacterial resistance to complement-mediated killing. IV. C5b-9 forms high molecular weight complexes with bacterial outer membrane constituents on serum-resistant but not on serum-sensitive Neisseria gonorrhoeae. J Immunol 131 3 (1983) 1443-1451
47. Ram S., Cox A.D., Wright J.C., Vogel U., Getzlaff S., Boden R., et al. Neisserial lipooligosaccharide is a target for complement component C4b. Inner core phosphoethanolamine residues define C4b linkage specificity. J Biol Chem 278 51 (2003) 50853-50862
48. Estabrook M.M., Jarvis G.A., and McLeod Griffiss J. Affinity-purified human immunoglobulin G that binds a lacto-N-neotetraose-dependent lipooligosaccharide structure is bactericidal for serogroup B Neisseria meningitidis. Infect Immun 75 2 (2007) 1025-1033
49. Verheul A.F., Snippe H., and Poolman J.T. Meningococcal lipopolysaccharides: virulence factor and potential vaccine component. Microbiol Rev 57 1 (1993) 34-49
50. Gold R., Goldschneider I., Lepow M.L., Draper T.F., and Randolph M. Carriage of Neisseria meningitidis and Neisseria lactamica in infants and children. J Infect Dis 137 2 (1978) 112-121
51. Bennett J.S., Griffiths D.T., McCarthy N.D., Sleeman K.L., Jolley K.A., Crook D.W., et al. Genetic diversity and carriage dynamics of Neisseria lactamica in infants. Infect Immun 73 4 (2005) 2424-2432
52. Cartwright K.A., Stuart J.M., Jones D.M., and Noah N.D. The Stonehouse survey: nasopharyngeal carriage of meningococci and Neisseria lactamica. Epidemiol Infect 99 3 (1987) 591-601
53. Gorringe A., Halliwell D., Matheson M., Reddin K., Finney M., and Hudson M. The development of a meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles. Vaccine 23 17-18 (2005) 2210-2213
54. Tong Y., Reinhold V., Reinhold B., Brandt B., and Stein D.C. Structural and immunochemical characterization of the lipooligosaccharides expressed by Neisseria subflava 44. J Bacteriol 183 3 (2001) 942-950
55. Banerjee A., Wang R., Uljon S.N., Rice P.A., Gotschlich E.C., and Stein D.C. Identification of the gene (lgtG) encoding the lipooligosaccharide beta chain synthesizing glucosyl transferase from Neisseria gonorrhoeae. Proc Natl Acad Sci U S A 95 18 (1998) 10872-10877
56. Finney M., Vaughan T., Taylor S., Hudson M.J., Pratt C., Wheeler J.X., et al. Characterization of the key antigenic components and pre-clinical immune responses to a meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles. Hum Vaccine 3 5 (2007)
57. Welsch J.A., and Granoff D. Immunity to Neisseria meningitidis group B in adults despite lack of serum bactericidal antibody. Clin Vaccine Immunol 14 12 (2007) 1596-1602
58. Plested J.S., and Granoff D.M. Vaccine-induced opsonophagocytic immunity to Neisseria meningitidis group B. Clin Vaccine Immunol 15 5 (2008) 799-804